VI. Other Types of Cerebrovascular Disorders

Journal of Stroke and Cerebrovascular Diseases

Volumn 20, Issue 4 SUPPL., 2011, Pages

  Shinohara, Yukito ^a,h   Yanagihara, Takehiko ^b   Abe, Koji ^c   Yoshimine, Toshiki ^b   Fujinaka, Toshiyuki ^d   Chuma, Takayo ^e   Ochi, Fumio ^f   Nagayama, Masao ^g   Ogawa, Akira ⁱ   Suzuki, Norihiro ^j   Katayama, Yasuo ^k   Kimura, Akio ^j   Naritomi, Hiroaki ^d  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d Senri Chuou Hospital   (Japan)

^e Shiga Medical Center for Adult Diseases   (Japan)

^f Self Defense Forces Central Hospital   (Japan)

^g International University of Health and Welfare   (Japan)

^h Japan Stroke Society   (Japan)

ⁱ IWATE MEDICAL UNIVERSITY   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k NIPPON MEDICAL SCHOOL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; ARGATROBAN; CANDESARTAN; CLOPIDOGREL; DONEPEZIL; FIBRINOLYTIC AGENT; GALANTAMINE; HEPARIN; MEMANTINE; NEUROPROTECTIVE AGENT; NICERGOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORPHENAZONE; OZAGREL; WARFARIN;

ALZHEIMER DISEASE; ANTICOAGULANT THERAPY; ANTICONVULSANT THERAPY; ANTIHYPERTENSIVE THERAPY; AORTITIS; ARTERY DISSECTION; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN ANGIOGRAPHY; BRAIN EDEMA; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR DISEASE; CONSCIOUSNESS LEVEL; DEMENTIA; DIABETES MELLITUS; DISSECTING ANEURYSM; DIZZINESS; DRUG EFFICACY; EXTRACRANIAL ARTERY DISSECTION; FEVER; FIBRINOLYTIC THERAPY; FIBROMUSCULAR DYSPLASIA; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INTRACRANIAL HYPERTENSION; LIVER DISEASE; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MOYAMOYA DISEASE; MULTIINFARCT DEMENTIA; NEUROIMAGING; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PARADOXICAL CEREBRAL EMBOLISM; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; POSTMARKETING SURVEILLANCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; ULCER; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; WEIGHT REDUCTION;

EID: 80051748625     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2011.05.013     Document Type: Article

References (161)

1. Working Group on Guidelines for Intravenous rt-PA (Alteplase) Therapy, Committee for Improvement of Stroke Therapy/Social Insurance, Japan Stroke Society. Guideline for appropriate treatment with intravenous rt-PA (alteplase) therapy, October 2005. Jpn J Stroke 2005; 27: 327-354 (in Japanese)
2. Chen M, Caplan L. Intracranial dissections. Front Neurol Neurosci 2005;20:160-173
3. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007;38:2605-2611 (Pubitemid 47329646)
4. Forette F, SeuxML,Staessen JA, et al. Prevention ofdementia in the randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352: 1347-1351 (Pubitemid 28510916)
5. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163: 1069-1075 (Pubitemid 36548935)
6. Yamaura A, Yoshimoto T, Hashimoto N, et al. Nationwide Study of Nontraumatic Intracranial Arterial Dissection: Clinical Features and Outcome. Surg Cereb Stroke 1998;26:79-86 (in Japanese)
7. Takagi M. Cerebral arterial dissection. Rinsho Shinkeigaku 2005;45:846-848 (in Japanese) (Pubitemid 43154936)
8. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med 2001;344:898-906 (Pubitemid 32224399)
9. Norris JW. Extracranial arterial dissection: Anticoagulation is the treatment of choice. Stroke 2005;36:2041-2042 (Pubitemid 41266552)
10. Bassi P, Lattuada P, Gomitoni A. Cervical cerebral artery dissection: A multicenter prospective study (preliminary report). Neurol Sci 2003;24(Suppl 1):S4-S7 (Pubitemid 36621534)
11. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev 2003(3): CD000255
12. Dreier JP, Lurtzing F, Kappmeier M, et al. Delayed occlusion after internal carotid artery dissection under heparin. Cerebrovasc Dis 2004;18:296-303 (Pubitemid 39664253)
13. Georgiadis D, Baumgartner RW. Thrombolysis in cervical artery dissection. Front Neurol Neurosci 2005;20:140-146
14. Fessler AJ, Alberts MJ. Stroke treatment with tissue plasminogen activator in the setting of aortic dissection. Neurology 2000;54:1010 (Pubitemid 30111376)
15. Chen M, Caplan L. Intracranial dissections. Front Neurol Neurosci 2005;20:160-173
16. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007;38:2605-2611 (Pubitemid 47329646)
17. Metso TM, Metso AJ, Helenius J, et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke 2007;38:1837-1842 (Pubitemid 46847256)
18. Takagi M. Guideline for diagnosis and treatment of cerebral artery dissection. In Guideline for treatment of stroke in younger patients: National multicenter study of diagnosis, treatment and preventive strategy for stroke in younger generations. Osaka: National Cardiovascular Center, Department of Medicine, Cerebrovascular Division; p. 85-89 (in Japanese)
19. Yamawaki T. Cervicocephalic arterial dissection: Ischemic cerebrovascular disorder due to cervicocephalic artery dissection. Neuro Med 2003;59:385-391 (in Japanese)
20. Georgiadis D, Caso V, Baumgartner RW. Acute therapy and prevention of stroke in spontaneous carotid dissection. Clin Exp Hypertens 2006;28:365-370 (Pubitemid 44178512)
21. Lee VH, Brown RD Jr, Mandrekar JN, et al. Incidence and outcome of cervical artery dissection: A population-based study. Neurology 2006;67:1809-1812 (Pubitemid 44900757)
22. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention. Circulation 2006;113:e409-e449 (Pubitemid 43739468)
23. Ono J, Hirai S, Serizawa T, et al. Prognostic factors of ruptured intracranial arterial dissections in the vertebrobasilar system: analysis of factors related to rebleeding. Jpn J Neurosurg 2002;11:265-270 (in Japanese) (Pubitemid 34288993)
24. Anxionnat R, de Melo Neto JF, Bracard S, et al. Treatment of hemorrhagic intracranial dissections. Neurosurgery 2003;53:289-301 (Pubitemid 36950906)
25. Sugiu K, Tokunaga K, Watanabe K, et al. Emergent endovascular treatment of ruptured vertebral artery dissecting aneurysms. Neuroradiology 2005;47:158-164 (Pubitemid 40425122)
26. Mizutani T. The frontier of aneurysms and artery dissection treatments: Surgical treatment of aneurysms in the main branch of cerebral artery, particularly acute dissecting cerebral aneurysm. J Clin Exp Med 2001; suppl:101-105 (in Japanese)
27. Kurata A, Hagiwara H, Yuzawa I, et al. Clinical manifestations of ruptured dissecting vertebral aneurysm and benefit of coil embolization. Neurosurg Emerg 2004;9: 24-34 (in Japanese)
28. Sugiu K, Tokunaga K, Date I. Endovascular treatment for ruptured vertebral artery dissecting aneurysms. Neuro Surg 2004;32:1229-1238 (in Japanese) (Pubitemid 40013267)
29. Sugiu K, Tokunaga K, Watanabe K, et al. Endovascular treatment of ruptured vertebral artery dissecting aneurysms: its usefulness and lessons from complications. Surg Cereb Stroke 2005;33:200-205 (in Japanese)
30. Tanabe H, Tamura Y, Sumioka S, et al. Direct surgery for dissecting vertebral aneurysms involving PICA. Surg Cereb Stroke 2005;33:147-154 (in Japanese)
31. Ono J, Yamaura A, Kobayashi S, et al. The state of the art (Brain attack). Dissection of cerebral artery. The treatment strategy for ruptured dissecting aneurysm - from the analysis of 62 patients with vertebrobasilar artery dissecting aneurysm. The Mt. Fuji workshop on CVD, 2000;18:95-98 (in Japanese)
32. Yamada M, Kitahara T, Kurata A, et al. Intracranial vertebral artery dissection with subarachnoid hemorrhage: Clinical characteristics and outcomes in conservatively treated patients. J Neurosurg 2004;101:25-30 (Pubitemid 38808456)
33. Yamaura A, Yoshimoto T, Hashimoto N, et al. Nationwide study of nontraumatic intracranial arterial dissection: clinical features and outcome. Surg Cereb Stroke 1998;26: 79-86 (in Japanese)
34. Yagi S, Yoshioka H, Yagi T, et al. Management of intracranial vertebral artery dissections presenting with isolated pain. Surg Cereb Stroke 2005;33:14-19 (in Japanese)
35. Naito I, Takatama S, Miyamoto N, et al. Treatment of unruptured vertebral artery dissecting aneurysms. Surg for Cerebral Stroke 2005;33:406-413 (in Japanese)
36. Yasui T, Kishi H, Komiyama M, et al. The state of the art (Brain attack). Treatment strategy for ruptured dissecting vertebral aneurysm in acute phase. The Mt Fuji Workshop on CVD 2000;18:92-94 (in Japanese)
37. Nakamura M, Fujita A, Kohmura E, et al. Embolization of Aneurysmal Dilatations for Vertebral Artery Dissections. Surg Cereb Stroke 2005;33:167-173 (in Japanese)
38. Rabinov JD, Hellinger FR, Morris PP, et al. Endovascular management of vertebrobasilar dissecting aneurysms. AJNR Am J Neuroradiol 2003;24:1421-1428 (Pubitemid 37012841)
39. Iihara K, Sakai N, Murao K, et al. Dissecting aneurysms of the vertebral artery: A management strategy. J Neurosurg 2002;97:259-267 (Pubitemid 34827323)
40. Mahmood A, Dujovny M, Torche M, et al. Microvascular anatomy of foramen caecum medulla oblongatae. J Neurosurg 1991;75:299-304
41. Felber S, Henkes H, Weber W, et al. Treatment of extracranial and intracranial aneurysms and arteriovenous fistulae using stent grafts. Neurosurgery 2004;55:631-639
42. Joo JY, Ahn JY, Chung YS, et al. Treatment of intra- and extracranial arterial dissections using stents and embolization. Cardiovasc Intervent Radiol 2005;28:595-602 (Pubitemid 41367567)
43. Morimoto M, Iwama T, Hashimoto N, et al. Efficacy of direct revascularization in adult moyamoya disease: Haemodynamic evaluation by positron emission tomography. Acta Neurochir (Wien) 1999;141:377-384 (Pubitemid 29192186)
44. Miyamoto S, Nagata I, Karasawa J, et al. Long-term prognosis after direct bypass in moyamoya disease. Surg Cereb Stroke 2000;28:111-114 (in Japanese)
45. Choi JU, Kim DS, Kim EY, et al. Natural history of moyamoya disease: Comparison of activity of daily living in surgery and nonsurgery groups. Clin Neurol Neurosurg 1997;99(Suppl 2):S11-S18 (Pubitemid 27489055)
46. Scott RM, Smith JL, Robertson RL, et al. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100(2 Suppl):142-149 (Pubitemid 38141339)
47. Matsushima Y, Aoyagi M, Nariai T, et al. Long-term prognosis of intelligence in childhood moyamoya patients evaluated by Wechsler tests, II: Childhood moyamoya patients who underwent encephalo-duro-arteriosynangiosis (EDAS) more than 10 years previously. Nerv Syst Child 1996;21:232-238
48. Kawaguchi T, Fujita S, Hosoda K, et al. Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 1996;84:468-476 (Pubitemid 26062873)
49. Houkin K, Kuroda S, Nakayama N. Cerebral revascularization for moyamoya disease in children. Neurosurg Clin North Am 2001;12:575-584 (Pubitemid 32601862)
50. Kuroda S, Houkin K, Kamiyama H, et al. Regional cerebral hemodynamics in childhood moyamoya disease. Childs Nerv Syst 1995;11:584-590
51. Ikezaki K, Matsushima T, Kuwabara Y, et al. Cerebral circulation and oxygen metabolism in childhood moyamoya disease: A perioperative positron emission tomography study. J Neurosurg 1994;81:843-850 (Pubitemid 24373464)
52. Mizoi K, Kayama T, Yoshimoto T, et al. Indirect revascularization for moyamoya disease: Is there a beneficial effect for adult patients? Surg Neurol 1996;45:548-549
53. Matsushima T, Inoue T, Suzuki SO, et al. Surgical treatment of moyamoya disease in pediatric patients: Comparison between the results of indirect and direct revascularization procedures. Neurosurgery 1992;31:401-405
54. Ishikawa T, Houkin K, Kamiyama H, et al. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke 1997;28:1170-1173 (Pubitemid 27248890)
55. Iwama T, Hashimoto N, Yonekawa Y. The relevance of hemodynamic factors to perioperative ischemic complications in childhood moyamoya disease. Neurosurgery 1996;38:1120-1126 (Pubitemid 26162756)
56. FujimuraM, Kaneta T, Mugikura S, et al. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery: Middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 2007;67:273-282 (Pubitemid 46274903)
57. Houkin K, Nakayama N, Kuroda S, et al. How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst 2004;20:734-741 (Pubitemid 39378343)
58. Honda M, Kitagawa N, Tsutsumi K, et al. Magnetic resonance angiography evaluation of external carotid artery tributaries in moyamoya disease. Surg Neurol 2005;64:325-330 (Pubitemid 41337895)
59. Working Group on Guidelines for Intravenous rt-PA (Alteplase) Therapy, Committee for Improvement of Stroke Therapy/Social Insurance, Japan Stroke Society. Guideline for appropriate treatment with intravenous rt-PA (alteplase) therapy, October 2005. Jpn J Stroke 2005; 27:327-354 (in Japanese)
60. DeVeber G. In pursuit of evidence-based treatments for pediatric stroke: The UK and Chest guidelines. Lancet Neurol 2005;4:432-436
61. Kikuta K, Takagi Y, Nozaki K, et al. Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study. J Neurosurg 2005;102:470-475 (Pubitemid 43194038)
62. Soman T, Rafay MF, Hune S, et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 2006;37:1120-1122
63. Kuroda S, Hashimoto N, Yoshimoto T, et al. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: Results of multicenter survey in Japan. Stroke 2007;38:1430-1435 (Pubitemid 46684140)
64. Han DH, Kwon OK, Byun BJ, et al; Korean Society for Cerebrovascular Disease. A co-operative study: Clinical characteristics of 334 Korean patients with moyamoya disease treated at neurosurgical institutes (1976-1994). Acta Neurochir (Wien) 2000;142:1263-1273
65. Kobayashi E, Saeki N, Oishi H, et al. Long-term natural history of hemorrhagic moyamoya disease in 42 patients. J Neurosurg 2000;93:976-980 (Pubitemid 32800606)
66. Kuroda S, Houkin K, Kamiyama H, et al. Effects of surgical revascularization on peripheral artery aneurysms in moyamoya disease: Report of three cases. Neurosurgery 2001;49:463-467
67. Houkin K, Kamiyama H, Abe H, et al. Surgical therapy for adult moyamoya disease: Can surgical revascularization prevent the recurrence of intracerebral hemorrhage? Stroke 1996;27:1342-1346 (Pubitemid 26286165)
68. Miyamoto S, Akiyama Y, Nagata I, et al. Long-term outcome after STA-MCA anastomosis for moyamoya disease. Neurosurg Focus 1998;5:e5. (http://thejns.org/doi/pdf/10.3171/foc.1998.5.5.8)
69. Karasawa J, Hosoi K. Revascularization in adult hemorrhagic moyamoya disease; In: Report from study group on etiology and pathology of spontaneous occlusion of the circle of Willis. (Japanese Ministry of Health Labour and Welfare). Results in FY2000. 2001, p. 55-58 (in Japanese)
70. Kawaguchi S, Okuno S, Sakaki T. Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease. J Neurosurg 2000;93:397-401
71. Nakagawa I, Kawaguchi S, Iida J, et al. Direct bypass of STA-MCA anastomosis prevents future stroke in patients with the hemorrhagic type of moyamoya disease. Surg Cereb Stroke 2004;32:416-420 (in Japanese)
72. Suzuki S, Matsushima T, Ikezaki K, et al. Surgical treatment of moyamoya disease in adults: Focusing on hemorrhagic type. Surg Cereb Stroke 1992;20:463-467 (in Japanese)
73. Yoshida Y, Yoshimoto T, Shirane R, et al. Clinical course, surgical management, and long-term outcome of moyamoya patients with rebleeding after an episode of intracerebral hemorrhage: An extensive follow-up study. Stroke 1999;30:2272-2276 (Pubitemid 29517720)
74. Fujii K, Ikezaki K, Irikura K, et al. The efficacy of bypass surgery for the patients with hemorrhagic moyamoya disease. Clin Neurol Neurosurg 1997;99(Suppl 2):S194-S195 (Pubitemid 27489094)
75. Aoki N. Cerebrovascular bypass surgery for the treatment of moyamoya disease: Unsatisfactory outcome in the patients presenting with intracranial hemorrhage. Surg Neurol 1993;40:372-377 (Pubitemid 23314203)
76. Miyamoto S; Japan Adult Moyamoya Trial Group. Study design for a prospective randomized trial of extracranialintracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset. Neurol Med Chir (Tokyo) 2004;44:218-219 (Pubitemid 38619411)
77. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005;112:1063-1072
78. Yasaka M, Otsubo R, Oe H, et al. Is stroke a paradoxical embolism in patients with patent foramen ovale? Intern Med 2005;44:434-438 (Pubitemid 40895097)
79. Japanese Circulation Society. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2004). Circ J 2004;68(Suppl IV):1079-1134 (in Japanese)
80. Schulman S, Rhedin AS, Lindmarker P, et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665
81. Schulman S, Granqvist S, Holmstrom M, et al; Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398 (Pubitemid 27081901)
82. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907. Erratum: 341:298 (Pubitemid 29141050)
83. Agnelli G, Prandoni P, Santamaria MG, et al; Warfarin Optimal Duration Italian Trial Investigators.. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169 (Pubitemid 32662124)
84. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. Intern Med 2001;40:1183-1188 (Pubitemid 34110494)
85. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348: 1425-1434 (Pubitemid 36407171)
86. Nagano K, Otsubo R, Yasaka M, et al. Stroke recurrence in patients with brain embolism and patent foramen ovale: Association with deep vein thrombosis detected by ultrasonography. Rinsho Shinkeigaku 2004;44:7-13 (in Japanese) (Pubitemid 38864726)
87. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746
88. Kanda N, Yasaka M, Otsubo R, et al. Right-to-left shunt and atrial septal aneurysm in stroke patients: A contrast transesophageal echocardiographic study. Rinsho Shinkeigaku 1998;38:213-218 (in Japanese) (Pubitemid 28312021)
89. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-2631 (Pubitemid 34596039)
90. Nedeltchev K, Arnold M, Wahl A, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 2002;72:347-350
91. Orgera MA, OMalley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: Systematic review and meta-analysis. South Med J 2001;94:699-703 (Pubitemid 33645043)
92. Klotz S, Tjan TD, Berendes E, et al. Surgical closure of combined symptomatic patent foramen ovale and atrial septum aneurysm for prevention of recurrent cerebral emboli. J Card Surg 2005;20:370-374 (Pubitemid 40992561)
93. Morandi E, Anzola GP, Angeli S, et al. Transcatheter closure of patent foramen ovale: A new migraine treatment? J Interv Cardiol 2003;16:39-42 (Pubitemid 36293092)
94. Chatterjee T, Petzsch M, Ince H, et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005;18:173-179 (Pubitemid 40942728)
95. Demkow M, Ruzyllo W, Kepka C, et al. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Kardiol Pol 2004;61:101-109 (Pubitemid 39128176)
96. Kimura K, Minematsu K, Nakajima M. Isolated pulmonary arteriovenous fistula without Rendu-Osler-Weber disease as a cause of cryptogenic stroke. J Neurol Neurosurg Psychiatry 2004;75:311-313 (Pubitemid 38183547)
97. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338: 597-600
98. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30: 484-488 (Pubitemid 29115380)
99. Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction: Factors affecting the initiation and safety of anticoagulation. Cerebrovasc Dis 1998;8:25-30 (Pubitemid 28046073)
100. Einhaupl K, Bousser MG, de Bruijn SF, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 2006;13:553-559 (Pubitemid 43873627)
101. Stam J, de Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2002(4):CD002005
102. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, cosponsored by the Council on Cardiovascular Radiology and Intervention. Stroke 2006;37:577-617 (Pubitemid 43732031)
103. Canhao P, Falcao F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: A systematic review. Cerebrovasc Dis 2003;15:159-166 (Pubitemid 36351200)
104. Ciccone A, Canhao P, Falcao F, et al. Thrombolysis for cerebral vein and dural sinus thrombosis. Cochrane Database Syst Rev 2004(1):CD003693
105. Frey JL, Muro GJ, McDougall CG, et al. Cerebral venous thrombosis: Combined intrathrombus rtPA and intravenous heparin. Stroke 1999;30:489-494 (Pubitemid 29115381)
106. Kwan J, Guenther A. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 2006(3): CD005501
107. Matkovic Z, Davis S, Gonzales M, et al. Surgical risk of hemorrhage in cerebral amyloid angiopathy. Stroke 1991;22:456-461
108. Izumihara A, Ishihara T, Iwamoto N, et al. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999;30:29-33 (Pubitemid 29029437)
109. Leblanc R, Preul M, Robitaille Y, et al. Surgical considerations in cerebral amyloid angiopathy. Neurosurgery 1991;29:712-718
110. Lee SH, Kim SM, Kim N, et al. Cortico-subcortical distribution of microbleeds is different between hypertension and cerebral amyloid angiopathy. J Neurol Sci 2007;258:111-114 (Pubitemid 46874485)
111. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: Preliminary results of a population-based study. Stroke 2002;33:1190-1196
112. O Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-245 (Pubitemid 30058955)
113. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004;3:484-492 (Pubitemid 38903099)
114. Rosand J, Hylek EM, ODonnell HC, et al. Warfarinassociated hemorrhage and cerebral amyloid angiopathy: Agenetic and pathologic study. Neurology 2000;55: 947-951
115. Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250-256 (Pubitemid 38167002)
116. Scolding NJ, Joseph F, Kirby PA, et al.Ab-related angiitis: Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128: 500-515 (Pubitemid 40380186)
117. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007;68:1411-1416 (Pubitemid 46661556)
118. Hirohata M, Yoshita M, Ishida C, et al. Clinical features of non-hypertensive lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Eur J Neurol 2010;17:823-829
119. Olin JW. Recognizing and managing fibromuscular dysplasia. Cleve Clin J Med 2007;74:273-274, 277-282
120. Arning C, Grzyska U. Color Doppler imaging of cervicocephalic fibromuscular dysplasia. Cardiovasc Ultrasound 2004;2:7. http://www. cardiovascularultrasound. com/content/2/1/7
121. Van Damme H, Sakalihasan N, Limet R. Fibromuscular dysplasia of the internal carotid artery: Personal experience with 13 cases and literature review. Acta Chir Belg 1999;99:163-168
122. Chiche L, Bahnini A, Koskas F, et al. Occlusive fibromuscular disease of arteries supplying the brain: Results of surgical treatment. Ann Vasc Surg 1997;11:496-504 (Pubitemid 27402628)
123. Curry TK, Messina LM. Fibromuscular dysplasia:When is intervention warranted? Semin Vasc Surg 2003;16:190-199 (Pubitemid 37129830)
124. Stewart MT, Moritz MW, Smith RB 3rd, et al. The natural history of carotid fibromuscular dysplasia. J Vasc Surg 1986;3:305-310 (Pubitemid 16159811)
125. Wells RP, Smith RR. Fibromuscular dysplasia of the internal carotid artery: A long-term follow-up. Neurosurgery 1982;10:39-43 (Pubitemid 12212272)
126. Plouin PF, Perdu J, La Batide-Alanore A, et al. Fibromuscular dysplasia. Orphanet J Rare Dis 2007;2:28. http://ojrd.com/content/2/1/28
127. Japan Intractable Diseases Research Foundation, Japanese Intractable Diseases Information Center. Takayasu arteritis. Available from: http://www.nanbyou.or.jp/sikkan/. Accessed January 16, 2009
128. Kim HJ, Suh DC, Kim JK, et al. Correlation of neurological manifestations of Takayasus arteritis with cerebral angiographic findings. Clin Imaging 2005;29:79-85 (Pubitemid 40332571)
129. Kumral E, Evyapan D, Aksu K, et al. Microembolus detection in patients with Takayasus arteritis. Stroke 2002;33:712-716 (Pubitemid 34203995)
130. Tada Y, Sato O, Ohshima A, et al. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl 1992;7:159-167
131. Matsumoto T, Yamada K, Mase M, et al. New surgical approach to Takayasus arteritis: Internal thoracic-carotid bypass surgery. Surg Cereb Stroke 1998;26:206-210 (in Japanese)
132. Mase M, Yamada K, Umemura A, et al. Treatment strategy for large vessel diseases, present status and future prospect: Revascularization of carotid occlusions associated with aortitis syndrome. Mt Fuji Workshop on CVD 2003;21:27-32 (in Japanese)
133. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572 (Pubitemid 37430158)
134. Cerebral symptoms and blood pressure during parenteral administration of chlorpromazine, dihydralazine and diazoxide. Danish Multicentre Study on Acute Severe Hypertension. Acta Med Scand Suppl 1983;678:51-60
135. McNaire A, Krogsgaard AR, Hilden T, Nielsen PE. Reversibility of cerebral symptoms in severe hypertension in relation to acute antihypertensive therapy. Danish Multicenter Study. Acta Med Scand 1986;220:25-31 (Pubitemid 16041843)
136. McNair A, Krogsgaard AR, Hilden T, Nielsen PE. Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study. Acta Med Scand 1986;220:15-23 (Pubitemid 16041842)
137. McNair A, Krogsgaard AR, Hilden T, Nielsen PE. Reversibility of cerebral symptoms in severe hypertension in relation to acute antihypertensive therapy. Danish Multicenter Study. Acta Med Scand Suppl 1985;693:107-110 (Pubitemid 15143067)
138. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in the randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 1998;352:1347-1351 (Pubitemid 28510916)
139. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on Cognition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18:1052-1059 (Pubitemid 41139903)
140. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovasculardisease. Arch InternMed 2003;163:1069-1075 (Pubitemid 36548935)
141. Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004;59:863-868 (Pubitemid 38333676)
142. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-1134
143. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006;20:177-185
144. McGuinness B, Todd S, Passmore P, et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006(2):CD004034
145. Beard CM, Waring SC, OBrien PC, et al. Nonsteroidal anti-inflammatory drug use and Alzheimers disease: A case-control study in Rochester, Minnesota, 1980 through. Mayo Clin Proc 1998;73:951-955
146. Nelson M, Reid C, Beilin L, et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003;20:897-903 (Pubitemid 37340282)
147. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443
148. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: The Cardiovascular Health Study. Arch Neurol 2005;62:1047-1051 (Pubitemid 41043724)
149. Suribhatla S, Dennis MS, Potter JF. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005;229-230:147-150 (Pubitemid 40341578)
150. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 2003;61:479-486 (Pubitemid 37025364)
151. Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: Combined analysis of two large-scale clinical trials.DementGeriatr Cogn Disord 2005;20:338-344 (Pubitemid 41642791)
152. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimers disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359:1283-1290 (Pubitemid 34310633)
153. Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: A randomized trial. Neurology 2007;69:448-458 (Pubitemid 47450280)
154. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208
155. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-1839 (Pubitemid 34761071)
156. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo- controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-305 (Pubitemid 35283717)
157. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-792 (Pubitemid 47243710)
158. Bes A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313-322 (Pubitemid 29250991)
159. Pantoni L, Bianchi C, Beneke M, et al. The Scandinavian Multi-Infarct Dementia Trial: A double-blind, placebocontrolled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000;175:116-123 (Pubitemid 30265478)
160. Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry 1996;29:47-56 (Pubitemid 26116561)
161. Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66:248-252 (Pubitemid 40314333)